Oncothyreon regains compliance with NASDAQ minimum bid listing requirement

Wednesday, January 2, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BELLEVUE, WA, Jan. 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ:ONTY, TSX:ONY) today announced that it has received a letter from The NasdaqStock Market, indicating that the Company has regained compliance with the$1.00 per share minimum closing bid price requirement for continued listing onthe Nasdaq Global Market, pursuant to Nasdaq Marketplace Rule 4450(a)(5). Inthe letter, Nasdaq advised the Company that this matter is now closed.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development ofinnovative therapeutic products for the treatment of cancer. Oncothyreon'sgoal is to develop and commercialize novel synthetic vaccines and targetedsmall molecules that have the potential to improve the lives and outcomes ofcancer patients. For more information visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook